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ABSTRACT
Objectives: The aim of the study was to analyze the M235T polymorphism of the angiotensinogen (AGT) gene in women 
with endometriosis and to identify correlations between identified genotypes and the disease progression, its stage and 
clinical course as well as to evaluate the prognostic value of the investigated polymorphism in patients with endometriosis 
treated for infertility.
Material and methods: The study group consisted of 241 women with minimal to severe stage of endometriosis, the 
control group (without endometriosis) — 127. The molecular analysis was performed by PCR-RFLP technique.
Results: The analysis of the frequency of genotypes and alleles of M235T polymorphism showed no significant differences 
between the study and the control groups and between the severity grades of the disease (p > 0.05). No such differences 
were reported in the case of different localizations of the disease lesions, either. Evaluation of the correlations related to 
pain accompanying endometriosis did not demonstrate association with any genotypes of the analyzed AGT gene poly-
morphism. Comparison of the results obtained in the group in which infertility treatment was successful (n = 54) and in 
those who failed to conceive (n = 73) did not show the correlation between the investigated polymorphism and the effect 
of infertility treatment.
Conclusions: M235T polymorphism of the AGT gene seems unrelated to the development or the clinical course of en-
dometriosis. No prognostic value has been found of the investigated polymorphism in predicting the effects of infertility 
treatment in women with endometriosis.
Key words: endometriosis, RAS system, angiotensinogen, gene polymorphism, infertility 
Ginekologia Polska 2017; 88, 11: 585–590
Corresponding author:
Liliana Kowalczyńska
Department of Biology and Medical Genetics, Medical University of Lodz
Hallera Sq. 1, 90–647 Lodz, Poland
tel./fax: 0048 042 6330594 
e-mail: liliana.kowalczynska@gmail.com
INTRODUCTION
Endometriosis is a chronic disease characterized by the 
presence of endometrial implants outside the uterus, most 
commonly in the peritoneum, pelvis and ovaries where cysts 
are often formed. It affects about 10% of women in their 
reproductive years [1, 2]. Clinically it is often manifested by 
chronic pain (menstrual, perimenstrual, dyspareunia, pelvic 
pain) and fertility problems. It is estimated that 30–50% 
of women with endometriosis have difficulty getting pre-
gnant [3, 4]. The amount of pain a woman experiences is 
not necessarily related to the severity of the disease. Some 
women with severe endometriosis may experience no pain, 
while others with a milder form of the disease may have 
severe pain [1]. 
Endometriosis was first described more than three cen-
turies ago [5]. Despite intense research over many years, the 
etiopathogenesis of this disease remains unclear. The most 
common hypothesis for the development of endometriosis 
is Sampson’s theory, which assumes that during menstru-
ation some of the exfoliated mucosal cells flow backwards 
through the fallopian tubes into the abdomen, where they 
take root and grow [3, 6]. Other frequently mentioned and 
already classical theories explaining the development of en-
dometriosis are the theory of metaplasia and the theory of 
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induction. The involvement of immune and environmental 
factors is also indicated [2, 7]. Furthermore, risk factors for 
disease development and progression include, among others, 
Caucasian race, age 25 to 35 years, positive family history of 
endometriosis, early menarche (below 11 years of age) and 
short menstrual cycles (less than 25 days) with heavy bleeding 
[8, 9]. The genetic background is also important. Numerous 
studies have proven that endometriosis can be classified 
as hereditary. It occurs more frequently in women whose 
first-degree relatives also have endometriosis [2]. These as-
sumptions are also confirmed in the study on monozygotic 
twins [10]. Furthermore, the importance of angiogenesis in 
the development and survival of endometriosis in the peri-
toneal cavity has been emphasized in recent years [11, 12]. 
In the hormonal cascade of the renin-angiotensin system 
(RAS), the angiotensinogen is released from the liver and cle-
aved in the peripheral blood by renin to form the decapeptide 
angiotensin I. Angiotensin I is then converted, by removal of 
two end-terminal amino acids, to form an octapeptide angio-
tensin II (Ang II) by the angiotensin-converting enzyme (ACE). 
Ang II is considered to be the most active component of RAS. 
Angiotensin II exerts its actions on different tissues and organs 
by interacting with two major subtypes of G protein-coupled 
receptors — angiotensin II type 1 and type 2 receptors (AT1R 
and AT2R) [13]. One of the effects of the activation of these 
receptors is the stimulation of the synthesis of vascular en-
dothelial growth factors (VEGF) which directly induce the 
formation of new blood vessels [14].
OBJECTIVES
The aim of this study was to analyze the M235T poly-
morphism of the angiotensinogen gene in women with en-
dometriosis and to determine the correlation between the 
identified genotypes and the stage of the disease as well as 
its clinical course. An attempt was also made to estimate the 
prognostic value of the analyzed polymorphism in patients 
with endometriosis treated for infertility.
MATERIAL AND METHODS
Subjects
The study group included 283 women, mean age 
32 years (range 17–52), treated at the Department of Ope-
rative Gynecology, Endoscopy and Gynecologic Oncology, 
Polish Mother’s Memorial Hospital-Research Institute in 
Lodz, diagnosed upon laparoscopic examination with diffe-
rent stages (I–IV) of endometriosis according to the revised 
American Fertility Society (rAFS) classification system which 
is characterized in Table 1 [15]. 
The control group consisted of 127 women (mean age 
39.6 ± 10.4, range 20–66) without endometriosis treated at 
the same Department.
The study protocol was approved by the Bioethical Com-
mittee of the Medical University of Lodz (RNN/421/12/KB).
Molecular analysis
Peripheral venous blood samples were collected from 
all subjects into tubes containing Na2EDTA. Genomic DNA 
was isolated from white blood cells, using the Blood Mini 
kit (DNA-Gdańsk, Poland) and stored at –20°C.
The M235T polymorphism of the angiotensinogen gene 
was typed by polymerase chain reaction-restriction frag-
ment length polymorphism (PCR-RFLP) analysis. A 165-bp 
DNA fragment containing the polymorphic site was ampli-
fied using forward primer 5’-CCG TTT GTG CAG GGC CTG GCT 
CTC T-3’ and reverse primer 5’-GCC AGG GTG CTG TCC ACA 
CTG ACT CCC-3’. The PCR reaction was performed in a 50 μl 
volume containing 100 ng of each primer, 0.1 mM of dNTPs, 
1 × PCR buffer, 1.5 U of Taq polymerase (Fermentas) and 
50 ng of genomic DNA. The amplification conditions were 
as follows: 94°C for 7 min, 35 cycles of 94°C for 45 s, 65°C 
for 40 sec and 72°C for 40 sec, followed by final extension at 
72°C for 7 min (Genius, Techne). A 10 μl aliquot of the PCR 
product mixtures was digested with 1 U of FastDigest BoxI 
(Thermo Scientific) restriction enzyme for 20 minutes. Dige-
stion products were visualized through ethidium bromide 
staining after electrophoresis in 2% agarose gels. The elec-
trophoresis revealed a 165 bp fragment for the homozy-
gotes (MM), 165 and 141 bp fragments for heterozygotes 
(MT) and 141 bp fragment for homozygotes (TT). The 24 bp 
fragment was not seen after digestion.
Statistical analysis
The statistical analysis was performed using Statistica 
10.0 pl. The chi2 test was applied in statistical calculations 
Table 1. Characterization of the study group (women with endometriosis)
Endometriosis stage Number of patients Mean age Range of age
I 61 31.8 ± 4.8 21–45
II 61 33.5 ± 5.8 24–52
III 91 32.5 ± 6.7 17–50
IV 70 31.2 ± 5.4 20–46
Total 283 32.3 ± 5.9 17–52
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for the analysis of variables. P < 0.05 was considered stati-
stically significant. 
RESULTS
To accomplish the research goal related to the evalu-
ation of the correlation between the M235T polymorphism 
of the angiotensinogen gene and the development and pro-
gression of endometriosis there were examined 283 patients 
with a diagnosed disease and 127 control women without 
endometriosis. The frequency of the analyzed genotypes 
(MM, MT, TT) did not demonstrate statistically significant dif-
ferences between the control and the study group (p = 0.15) 
(Table 2). Similarly, no differences were found between the 
four stages of the disease (p = 0.68) (Table 2). Furthermore, 
the frequency of AGT gene M and T alleles were determined 
in the analyzed systems but statistically significant differ-
ences were not apparent, either (Table 2). 
Due to the lack of statistical differences in the analyzed 
systems, two additional subgroups were distinguished in the 
study group: A (n = 122) including patients with stage I and 
II and group B (n = 161) with stage III and IV of endometriosis 
acc. to the rAFS classification system [15]. In this case, in 
group A the distribution of M235T polymorphism of the AGT 
gene was the following: MM — 25.41% MT — 51.64%, 
TT — 22.95%, whereas in group B: MM — 25.47%, MT 
— 55.28%, TT — 19.25% and the distribution of the alleles 
was respectively: M — 51.23%, T — 48.77% and M — 53.11%, 
T — 46.89%. The distributions did not differ significantly 
(respectively p = 0.73; p = 0.66). 
Analysis of the frequency of genotypes and alleles of 
M235T polymorphism of the angiotensinogen gene in as-
sociation with the number of endometriosis localizations 
is presented in Table 3. It showed no significant differences 
between the groups (p = 0.19, p = 0.90 respectively for 
genotypes and alleles). 
In the medical history of women enrolled in the study 
(taken from 188 women) 121 reported severe pelvic pain, 
whereas 67 had no such complaints. In these groups, the 
frequency of genotypes of the investigated AGT gene poly-
morphism was analyzed. In the group with pelvic pain the 
frequency of MM genotype was 31.40%, MT — 48.76%, 
TT — 19.83% and in the group without pain respectively 
26.87%, 50.75%, 22.39%. These results did not differ statisti-
cally significantly (p = 0.79). 
Infertility was also present in the study group (n = 127, 
44.88%). These women underwent a laparoscopic surgical 
procedure to remove the foci of endometriosis. In 54 women 
the treatment was successful (the patients became pregnant 
and carried to term) and 73 women did not achieve the ex-
pected result. Both groups were compared in terms of the 
frequencies of AGT (M235T) polymorphic genotypes. The fre-
quencies were the following: MM — 27.78%, MT — 44.44%, T
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TT — 27.78% and MM — 17.81%, MT — 57.53%, TT — 24.66%, 
respectively for women with positive response to the treat-
ment and no response. The observed differences were not 
statistically significant (p = 0.28). 
DISCUSSION
Endometriosis is a disease characterized by the presence 
of an ectopic endometrium outside the uterine cavity. En-
dometrium is one of the few tissues in the human body that 
undergoes rapid cyclic growth and regression. This process 
involves the formation of new blood vessels. Endometrial 
implants require good blood supply to survive and grow. 
Thus, it is assumed that angiogenesis plays an important 
role in the pathogenesis of this disease, as confirmed by 
studies showing that endometrial implants are surrounded 
by a dense web of blood vessels [11, 12]. 
There are several studies on the involvement of renin-
-angiotensin system in the physiologic and pathologic an-
giogenesis. It is known that RAS-dependent formation of 
new blood vessels is indirect because activated angiotensin 
II receptors induce the expression of VEGF which is a potent 
pro-angiogenic factor [14]. This process appears to be tis-
sue-specific [11]. 
Due to the hereditary nature of the disease, over the 
past several decades there has been a search for genes of 
specific sequence that could be associated with an incre-
ased risk of endometriosis. Among the tested genes are e.g. 
genes encoding proteins involved in cell cycle regulation 
and apoptosis, growth factors, extracellular matrix enzy-
mes, adhesion proteins and cytokines [16]. To date, at least 
eight single nucleotide polymorphisms (SNPs) have been 
described, which seem to be related to the development 
of endometriosis [17]. 
Molecular variant M235T is one of the variants of the 
angiotensinogen (AGT) gene. The effect of thymine (T) 
replacement by cytosine (C) in the 3’ region of exon 2 is 
the substitution of methionine (M) for threonine (T) in the 
encoded protein chain [18]. It appears that the T allele of 
the analyzed polymorphism has a functional effect and 
is associated with increased level of angiotensinogen in 
plasma [19, 20]. 
In this study, the frequency of M235T polymorphism of 
the AGT gene was analyzed in women with endometriosis. It 
should be considered as pioneering research as there have 
been no publications in the available world literature descri-
bing the above problem. The analysis comprised 283 women 
in different stages of the disease according to the revised 
American Fertility Society (rAFS) classification [15]. There were 
no significant differences observed between the study group 
and the control group, neither between the four stages of the 
disease (I–IV) (Table 2) nor between the subgroups: A (stage I 
and II) and B (stage III and IV). Thus, the obtained results do 
not show the correlation between the investigated polymor-
phism and the development of endometriosis. 
In available literature, there is no clear evidence of RAS 
involvement in the development and progression of en-
dometrial foci. The most widely studied component of this 
system is the angiotensin I-converting enzyme (ACE) gene, 
which describes several polymorphisms. Hsieh et al. studied 
the ACE insertion/deletion (I/D) gene polymorphisms in 
Asian women (n = 125) with stage III and IV endometriosis 
and compared the obtained results with the control group 
(n = 128) [21]. According to the authors, allele I both in 
homo- (II) and heterozygous (ID) systems increased the 
risk of endometriosis. Different results were obtained by 
the authors of this paper in their previous studies [22]. 
The study included 241 women with endometriosis (I–IV). 
Apart from the comparison of the frequency of I/D poly-
morphism distribution between the study and the control 
group (n = 127), its frequency between the four stages of 
the disease and between stage I and II and III and IV was 
also analyzed. The differences were not significant in any 
of the analyzed systems. The study also presented the re-
sults of the determination of the frequency of angiotensin 
I-converting enzyme gene A2350G polymorphism and the 
A1166C polymorphism of the angiotensin II receptor gene 
Table 3. Genotype and allele frequencies of AGT polymorphism in endometriosis patients with one, two, three, four and more endometriosis 
locations
One location
(n = 120)
No. (%)
Two locations 
(n = 89)
No. (%)
Three locations 
(n = 47)
No. (%)
Four and more locations 
(n = 27)
No. (%)
P value
M/T genotypes p = 0.19
MM 34 (28.33) 20 (22.47) 13 (27.66) 5 (18.52)
MT 55 (45.83) 57 (64.04) 23 (48.94) 17 (62.96)
TT 31 (25.83) 12 (13.48) 11 (23.40) 5 (18.52)
Allele p = 0.90
M 124 (51.24) 97 (54.49) 49 (52.13) 27 (50.00)
T 118 (48.76) 81 (45.51) 45 (47.87) 27 (50.00)
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(AT1). In the case of A1166C AT1 polymorphism, no associa-
tion was found between the polymorphism and the prob-
ability of the disease development. Whereas in the case of 
ACE A2350G polymorphism G allele and AG genotype but 
not GG, occurred significantly more frequently in the study 
group than in the control group (p < 0.0001). However, there 
were no differences in the frequency of individual alleles and 
genotypes between the different stages of the disease pro-
gression or between stage I and II and III and IV [22]. Hsieh et 
al. also observed that ACE A2350G gene polymorphism was 
associated with higher susceptibility to moderate/severe 
endometriosis in the Asian population [23]. In the same 
work the authors also analyzed another single-nucleotide 
polymorphism (A-240T) of the angiotensin I-converting 
enzyme gene located in the promoter region of the gene. 
In this case the T allele was significantly more frequently 
observed in women with endometriosis compared to the 
control group [23]. These results were not confirmed by the 
study performed in Estonia [24]. The study group (n = 150) 
included women with all four stages of the disease. The 
authors failed to demonstrate associations between the 
A2350G and A-240T polymorphisms of the ACE gene and 
the increased risk of endometriosis. 
Endometriosis is a disease that involves many different 
organs. Endometriosis foci can be localized in the perito-
neum, the ovaries, fallopian tubes, parametrium, uterosacral 
ligaments, rectovaginal septum and also outside the repro-
ductive organs [6, 16]. The reason why some women develop 
endometriosis in one location while others in several is 
not known. In this study the number of organs affected by 
endometrial lesions varied among the examined women. 
Thus, four subgroups were distinguished in the study group 
corresponding to one, two, three and four and more loca-
tions of endometriosis. Genotype and allele frequencies 
of M235T polymorphism of the angiotensinogen gene 
were analyzed in these subgroups (Table 3). The statistical 
analysis did not show any significant differences between 
the subgroups. The results of our study may suggest that 
the level of angiotensinogen associated with the analyzed 
polymorphism (presence of T allele means increased protein 
level) does not seem to affect the intensity of the neovas-
cularization observed in the process of endometrial foci 
development. 
According to the literature data endometriosis is diag-
nosed in 35–70% of women with chronic pelvic pain [3, 4]. 
Pain is a major symptom of endometriosis but its sensation 
is not identical in different patients. Some of them complain 
of very severe pain (painful menstrual periods, PMS, pelvic 
pain, dyspareunia), often cyclical, which is associated with 
changes in sex hormone levels during the menstrual cycle. 
Other patients, despite significant severity of the lesions 
experience no pain [1]. The pain associated with endome-
triosis on the one hand results from the innervation of en-
dometriotic deposits, on the other hand lesion-induced 
inflammatory process of nerve fibers is of significance. It 
appears that in the immediate vicinity and inside the endo-
metrial implants new nerve fibers are formed, accompanied 
by immature blood vessels [25]. The nerve growth factor 
(NGF) and vascular endothelial growth factor (VEGF), the 
levels of which are increased in the eutopic and ectopic 
endometrium of women with endometriosis, are involved 
in both neurogenesis and angiogenesis processes [1, 6, 25]. 
The above data suggest a possible involvement of the neo-
vascularization process in the perception of pain by women 
with endometriosis, that is why the authors of this study 
decided to check whether there is a correlation between 
the M235T polymorphism of the AGT gene and pain. 
In the present study, when taking medical history con-
cerning pelvic pain, 121 women enrolled in the study group 
reported pain, whereas 67 did not experience it. In this way, 
there were distinguished two groups that were compared 
as regards the frequency of the occurrence of genotypes 
of the investigated AGT gene polymorphism. Differences 
in the frequency of MM, MT, and TT genotypes were small 
and not statistically significant, suggesting that the investi-
gated angiotensinogen gene polymorphism does not play 
a significant role in the etiology of pain associated with 
endometriosis. 
Endometriosis is a disease that significantly impairs fer-
tility. Among the women suffering from it, as many as 30 to 
50% have problems with getting pregnant [3, 4]. Often, in 
the absence of other ailments, it is precisely the search for 
the reasons for failure to become pregnant that results in 
the diagnosis of endometriosis. In advanced endometriosis 
extensive adhesions and cysts may distort pelvic anatomy 
which in turn contributes to infertility. In patients with mini-
mal and moderate endometriosis anatomical changes no 
longer play a dominant role. Here the causes of infertility lie 
in inflammatory processes occurring within the peritoneal 
space [26]. 
In this research nearly half of the study group (n = 127, 
44.88%) presented with infertility problems. These women 
were treated to remove the lesions and restore fertility. In 
some of them (n = 54; 42.52%) the therapy brought the 
expected effect. Both groups (with and without response to 
the treatment) were compared in terms of the frequency of 
genotypes of M235T angiotensinogen gene polymorphism. 
The analyzed results were differentiated but they did not 
show statistically significant differences. This suggests lack 
of the prognostic value of the investigated polymorphism 
as to the predicted effect of the treatment of infertility co-
existing with endometriosis.
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 CONCLUSIONS
No correlation was found in this study between M235T 
angiotensinogen gene polymorphism and the development 
of endometriosis, its stage or clinical course. The prognostic 
value of the analyzed polymorphism in the prediction of 
effects of the treatment of infertility coexisting with endo-
metriosis has not been found, either.
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